[ad#PhycoBiosciences AIM Interview]

Innovations

Sealantis’ alga-mimetic sealant in clinical study

July 22, 2013
AlgaeIndustryMagazine.com

Seal-1

Haifa, Israel-based Sealantis Ltd., a private start-up emerging from the Technion-Israel Institute of Technology, reports that eight patients have now been treated with Seal-V, its alga-mimetic vascular sealant, as part of the company’s first clinical study.

Seal-V is a protein-free sealant, designed to resolve current limitations and challenges in the control of surgical bleeding. The clinical trial, taking place in Israel, is evaluating the safety and efficacy of achieving hemostasis in large peripheral blood vessels using the Seal-V protein-free sealant.

Sealantis is a 6-year-old startup, located on the campus of one of Israel’s leading academic centers — the Technion. Sealantis was founded by Prof. Havazelet Bianco-Peled, a world-renowned expert in biomedical polymers.

Since the early 2000s, Prof. Bianco-Peled had been researching the adhesion mechanism of algae to rocks underwater. The research unveiled the chemical composition of the algae adhesive, but it was the professor’s invention of a synthetic, alga-mimetic adhesive that enabled harnessing nature’s power for practical and commercial uses.

Seal-2

In 2007, the invention was embraced by the Alfred Mann Institute at the Technion (AMIT), which is funding the company. While having potential uses in a variety of industrial applications, Sealantis chose to focus on urgent medical needs –  controlling leakage of body fluids through surgical or traumatic wounds. Such leaks can be fatal since sutures or staples are not fully leak-proof. “Sealing surgical incisions requires sticking to wet or moist surfaces, which is a challenge that most known adhesives can’t usually meet,” said Prof. Bianco-Peled.

Surgical sealants represent a market of over $1.0 billion, which grows 14% annually. “When I look at the market, it’s clear to me that there is no single winning solution,” says Dr. Zeev Gilkis, AMIT CEO and Sealantis Ltd. Chairman. “There are some good products, but each one has drawbacks or is limited to a specific application. Sealantis brings a versatile yet simple technology, addressing unmet clinical needs.”

“Seal-V is overcoming a clinical need with its unique features, which offer simultaneous sealing and hemostasis for native and synthetic vascular fields,” said Prof. Vincent Riambau, Chief of Vascular Surgery Division, Hospital Clínic, University of Barcelona, and Past President of the European Society of Vascular Surgery (ESVS), who serves on the Clinical Advisory Board of Sealantis. “It is accomplishing valuable qualities for vascular surgery, being quick, easy to use, effective and safe. It will surely be most welcome to the vascular community.”

Sealantis Ltd. is currently planning its next regulatory steps toward a PMA study and FDA approval of Seal-V and is working on strategic partnerships towards the coming market launch.”

More Like This…

HOME Algae Industry Jobs

Copyright ©2010-2013 AlgaeIndustryMagazine.com. All rights reserved. Permission granted to reprint this article in its entirety. Must include copyright statement and live hyperlinks. Contact editorial@algaeindustrymagazine.com. A.I.M. accepts unsolicited manuscripts for consideration, and takes no responsibility for the validity of claims made in submitted editorial.

From The A.I.M. Archives

— Refresh Page for More Choices
Tess Riley writes in TheGuardian.com about how spirulina may be able to combat malnutrition in developing countries. Spirulina is one of the oldest life forms on Earth, c...
K. S. Rajgopal writes in thehindu.com about a new study that demonstrates how macroalgal biomass from Gelidiella acerosa and Gracilaria dura collected from Adri and Verav...
The U.S. Environmental Protection Agency (EPA) is developing an early warning indicator system using historical and current satellite data to detect algal blooms. EPA res...
The vision of developing a community college degree program to train a high technology algae workforce was launched at New Mexico's Santa Fe Community College (SFCC) in 2...
Studies conducted by EnAlgae partners in Ireland, France and Belgium point the way to seaweed being a viable and sustainable feedstock for the future in North West Europe...
With large-scale production at low cost a future possibility, many corporations in Japan are beginning to jump on the algae fuel bandwagon. Heavy industry giant IHI Corp....
Michigan State University (MSU) and PHYCO2, an algae growth and CO2 sequestration company based in Santa Maria, CA, have entered into a partnership to develop algae techn...
Hannah Osborne writes in the International Business Times that algae has been genetically engineered to kill cancer cells without harming healthy cells. The algae nanopar...
Ewen Callaway writes in the jounal Nature that restrictions on harvests and exports of Gelidium seaweed in Morocco have affected the global supply of the lab reagent agar...
Algatechnologies Ltd. has launched its AstaPure® 5% Natural Astaxanthin oleoresin, derived from Haematococcus pluvialis microalgae. This latest addition to the AstaPure f...
The new algae raceway testing facility, opening February 4 at Sandia National Laboratories in Livermore, California, paves a direct path between laboratory research and s...
Kailua Kona-based Cyanotech Corporation announced financial results for the third quarter and first nine months of fiscal year 2016, ended December 31, 2015. For the thir...